{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-004635","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2026-07-14T21:00:16+00:00","discovered_at":"2026-07-14T21:02:00.210082+00:00","generated_at":"2026-07-14T21:02:07.200255+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Anika Therapeutics enters Fifth Amendment to credit agreement, $50M revolver due 2031","bullets":["$50M senior revolving credit facility with Bank of America, maturity July 10, 2031.","Option to increase commitments by up to $50M (total $100M) subject to lender approval.","Interest rate: SOFR plus 0.25%-1.25% based on leverage ratio; commitment fee 0.20%-0.30% on unused portion.","Financial covenants include max leverage and interest coverage ratios; first-priority lien on substantially all assets.","Amendment reduces revolving facility from prior amount to $50M; certain lenders exit."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-004635","json":"https://secwatch.observer/filing/0001171843-26-004635.json","markdown":"https://secwatch.observer/filing/0001171843-26-004635.md","text":"https://secwatch.observer/filing/0001171843-26-004635.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184326004635/0001171843-26-004635-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184326004635/f8k_071426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-14T21:02:07.200255+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}